Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 30, 2024
Data Byte
Nine PDUFA dates on FDA’s agenda in September
Decision on Zevra’s arimoclomol follows positive AdCom vote
BioCentury | Jan 24, 2024
Data Byte
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024
A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | Apr 25, 2022
Data Byte
Mechanistic diversity in the pipeline for fragile X syndrome
The fragile X pipeline comprises as many drugs targets as drug candidates
BioCentury | Mar 4, 2022
Distillery Therapeutics
Targeting GABA signals for cancer checkpoint inhibitor resistance
BioCentury | Aug 13, 2021
Product Development
Aug. 12 Quick Takes: another hold for Aprea’s eprenetapopt
Plus Vyne, AlzeCure and Jazz
BioCentury | Oct 9, 2020
Deals
Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna
Kronos raises $250M in NASDAQ IPOLook for shares of Kronos Bio Inc. (NASDAQ:KRON) to begin trading on Friday after the company raised $250 million in an IPO. The listing completes a busy few months
BioCentury | Sep 25, 2020
Emerging Company Profile
XWPharma: timing therapy to biological rhythm
XWPharma to use $40M series C to advance two lead neurology programs
BioCentury | Jul 24, 2020
Product Development
July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit
BioCentury | Mar 27, 2020
Product Development
March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax
Items per page:
1 - 10 of 103